Candriam S.C.A. Decreases Stock Holdings in Dianthus Therapeutics, Inc. $DNTH

Candriam S.C.A. lowered its stake in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 31.4% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 213,522 shares of the company’s stock after selling 97,628 shares during the quarter. Candriam S.C.A.’s holdings in Dianthus Therapeutics were worth $17,919,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Raymond James Financial Inc. bought a new position in Dianthus Therapeutics in the second quarter worth about $27,000. First Horizon Corp purchased a new stake in Dianthus Therapeutics during the first quarter valued at approximately $32,000. Caitong International Asset Management Co. Ltd acquired a new stake in Dianthus Therapeutics in the fourth quarter valued at approximately $40,000. Russell Investments Group Ltd. acquired a new stake in Dianthus Therapeutics in the third quarter valued at approximately $64,000. Finally, Tower Research Capital LLC TRC grew its holdings in Dianthus Therapeutics by 330.7% in the second quarter. Tower Research Capital LLC TRC now owns 4,320 shares of the company’s stock worth $80,000 after purchasing an additional 3,317 shares during the last quarter. Hedge funds and other institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Stock Down 2.4%

Shares of Dianthus Therapeutics stock traded down $2.43 on Friday, reaching $97.60. 842,644 shares of the stock were exchanged, compared to its average volume of 1,351,040. The business has a 50 day moving average price of $87.77 and a two-hundred day moving average price of $71.75. The firm has a market capitalization of $5.34 billion, a price-to-earnings ratio of -23.63 and a beta of 1.20. Dianthus Therapeutics, Inc. has a twelve month low of $18.08 and a twelve month high of $102.33.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($0.85) earnings per share for the quarter, topping the consensus estimate of ($1.07) by $0.22. Dianthus Therapeutics had a negative net margin of 12,998.50% and a negative return on equity of 27.30%. The company had revenue of $0.46 million for the quarter, compared to the consensus estimate of $0.40 million. Research analysts forecast that Dianthus Therapeutics, Inc. will post -3.82 EPS for the current year.

Insiders Place Their Bets

In other news, SVP Adam M. Veness sold 30,000 shares of the stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $80.80, for a total value of $2,424,000.00. Following the sale, the senior vice president owned 30,000 shares in the company, valued at $2,424,000. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Simrat Randhawa sold 26,530 shares of the firm’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $90.62, for a total transaction of $2,404,148.60. Following the transaction, the executive vice president directly owned 4,000 shares of the company’s stock, valued at approximately $362,480. This trade represents a 86.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 3.02% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on DNTH shares. William Blair reiterated an “outperform” rating on shares of Dianthus Therapeutics in a report on Monday, March 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Dianthus Therapeutics in a report on Monday, April 20th. Wolfe Research restated an “outperform” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Wedbush increased their price objective on shares of Dianthus Therapeutics from $103.00 to $105.00 and gave the company an “outperform” rating in a research report on Wednesday, May 6th. Finally, TD Cowen reiterated a “buy” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Dianthus Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $117.82.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.